Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:FLGT NASDAQ:TOI NASDAQ:VMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$15.46-4.0%$14.61$3.44▼$20.21$156.28M0.431.02 million shs11,038 shsFLGTFulgent Genetics$15.67-1.0%$15.49$13.46▼$31.04$466.12M0.88502,285 shs187,318 shsTOIOncology Institute$3.89-2.9%$3.26$2.02▼$4.88$384.78M0.331.88 million shs331,342 shsVMDViemed Healthcare$9.10+0.8%$9.37$5.93▼$10.18$348.68M1.15252,136 shs43,379 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+5.16%+45.40%+22.70%+54.90%+112.70%FLGTFulgent Genetics-0.88%+11.96%+9.63%-31.40%-19.08%TOIOncology Institute+0.25%-0.99%+30.19%+49.63%+43.21%VMDViemed Healthcare+1.01%-9.43%-5.05%+8.93%+42.88%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$15.46-4.0%$14.61$3.44▼$20.21$156.28M0.431.02 million shs11,038 shsFLGTFulgent Genetics$15.67-1.0%$15.49$13.46▼$31.04$466.12M0.88502,285 shs187,318 shsTOIOncology Institute$3.89-2.9%$3.26$2.02▼$4.88$384.78M0.331.88 million shs331,342 shsVMDViemed Healthcare$9.10+0.8%$9.37$5.93▼$10.18$348.68M1.15252,136 shs43,379 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix+5.16%+45.40%+22.70%+54.90%+112.70%FLGTFulgent Genetics-0.88%+11.96%+9.63%-31.40%-19.08%TOIOncology Institute+0.25%-0.99%+30.19%+49.63%+43.21%VMDViemed Healthcare+1.01%-9.43%-5.05%+8.93%+42.88%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.67Moderate Buy$33.00113.48% UpsideFLGTFulgent Genetics 2.20Hold$27.0072.33% UpsideTOIOncology Institute 2.60Moderate Buy$7.0079.81% UpsideVMDViemed Healthcare 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest BDSX, FLGT, TOI, and VMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026FLGTFulgent Genetics Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$30.00 ➝ $15.005/5/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.005/4/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026TOIOncology Institute Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/13/2026TOIOncology Institute B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$6.00 ➝ $8.003/9/2026TOIOncology Institute BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.003/9/2026TOIOncology Institute Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.002/27/2026BDSXBiodesix William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform2/17/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.00(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$88.50M1.77N/AN/A($0.31) per share-49.86FLGTFulgent Genetics$322.67M1.44N/AN/A$35.80 per share0.44TOIOncology Institute$502.73M0.77N/AN/A($0.16) per share-24.33VMDViemed Healthcare$286.57M1.22$1.17 per share7.76$3.78 per share2.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%N/AFLGTFulgent Genetics-$60.51M-$2.39N/AN/AN/A-23.04%-3.24%-2.97%7/31/2026 (Estimated)TOIOncology Institute-$60.61M-$0.37N/AN/AN/A-7.42%N/A-24.89%N/AVMDViemed Healthcare$14.93M$0.3724.5815.17N/A5.20%10.52%7.60%N/ALatest BDSX, FLGT, TOI, and VMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TOIOncology Institute-$0.07-$0.02+$0.05-$0.02$142.10 million$147.44 million5/5/2026Q1 2026VMDViemed Healthcare$0.09$0.06-$0.03$0.06$74.40 million$75.41 million5/4/2026Q1 2026BDSXBiodesix-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million3/12/2026Q4 2025TOIOncology Institute-$0.08-$0.06+$0.02-$0.06$139.78 million$141.96 million3/4/2026Q4 2025VMDViemed Healthcare$0.12$0.14+$0.02$0.14$77.70 million$76.18 million2/27/2026Q4 2025FLGTFulgent Genetics$0.02$0.16+$0.14-$0.76$85.38 million$83.34 million2/26/2026Q4 2025BDSXBiodesix-$1.05-$0.49+$0.56-$0.49$26.25 million$28.76 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/AFLGTFulgent GeneticsN/AN/AN/AN/AN/ATOIOncology InstituteN/AN/AN/AN/AN/AVMDViemed HealthcareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix5.092.822.82FLGTFulgent GeneticsN/A5.315.31TOIOncology InstituteN/A1.591.35VMDViemed Healthcare0.061.221.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%FLGTFulgent Genetics48.06%TOIOncology Institute36.86%VMDViemed Healthcare74.24%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix23.20%FLGTFulgent Genetics36.18%TOIOncology Institute8.50%VMDViemed Healthcare20.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix22010.11 million7.76 millionNo DataFLGTFulgent Genetics1,31529.75 million18.99 millionOptionableTOIOncology Institute66098.84 million90.44 millionNot OptionableVMDViemed Healthcare1,38238.34 million30.67 millionNot OptionableBDSX, FLGT, TOI, and VMD HeadlinesRecent News About These CompaniesStonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 1Q261 hour ago | newsfilecorp.comNViemed Healthcare Q1 Earnings Call HighlightsMay 7, 2026 | marketbeat.comViemed Healthcare, Inc. (VMD) Q1 2026 Earnings Call TranscriptMay 6, 2026 | seekingalpha.comViemed (VMD) Q1 2026 Earnings TranscriptMay 6, 2026 | fool.comFinancial Review: Viemed Healthcare (NASDAQ:VMD) & BioLife Solutions (NASDAQ:BLFS)May 6, 2026 | americanbankingnews.comViemed Healthcare, Inc. (VMD) Q1 Earnings Miss EstimatesMay 5, 2026 | zacks.comViemed Healthcare (NASDAQ:VMD) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPSMay 5, 2026 | marketbeat.comViemed Healthcare Announces First Quarter 2026 Financial ResultsMay 5, 2026 | accessnewswire.comAViemed Healthcare (VMD) to Release Quarterly Earnings on TuesdayApril 28, 2026 | marketbeat.comViemed Healthcare Announces First Quarter 2026 Earnings Conference Call DetailsApril 21, 2026 | accessnewswire.comAViemed Healthcare (NASDAQ:VMD) Stock Price Down 0.8% - Should You Sell?April 21, 2026 | marketbeat.comViemed Healthcare (NASDAQ:VMD) President Sells $297,389.40 in StockMarch 21, 2026 | insidertrades.comViemed Healthcare to Present at Sidoti's Small-Cap Virtual Investor Conference March 18-19March 16, 2026 | accessnewswire.comAStonegate Capital Partners Updates Coverage on Viemed Healthcare, Inc. (VMD) 4Q 2025March 11, 2026 | newsfilecorp.comNViemed Healthcare, Inc. (NASDAQ:VMD) Q4 2025 earnings call transcriptMarch 6, 2026 | msn.comViemed Healthcare, Inc. (VMD) Q4 2025 Earnings Call TranscriptMarch 5, 2026 | seekingalpha.comViemed Healthcare Announces 2026 Share Repurchase ProgramMarch 4, 2026 | accessnewswire.comAViemed Healthcare Announces Record 2025 Financial ResultsMarch 4, 2026 | accessnewswire.comAViemed Healthcare Announces Year End 2025 Earnings Conference Call DetailsFebruary 24, 2026 | accessnewswire.comAStonegate Capital Partners Initiates Coverage on Viemed Healthcare, Inc. (VMD)January 6, 2026 | newsfilecorp.comNViemed Healthcare, Inc. (VMD) Q3 2025 Earnings Call TranscriptNovember 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 2026AMD’s Breakout Isn’t the Story—This Catalyst IsBy Thomas Hughes | April 24, 2026Anheuser-Busch Stock Jumps as Volume Growth Signals TurnaroundBy Chris Markoch | May 7, 2026BDSX, FLGT, TOI, and VMD Company DescriptionsBiodesix NASDAQ:BDSX$15.46 -0.65 (-4.05%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.Fulgent Genetics NASDAQ:FLGT$15.67 -0.15 (-0.96%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.Oncology Institute NASDAQ:TOI$3.89 -0.12 (-2.92%) As of 11:55 AM Eastern This is a fair market value price provided by Massive. Learn more.The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.Viemed Healthcare NASDAQ:VMD$9.10 +0.07 (+0.82%) As of 11:54 AM Eastern This is a fair market value price provided by Massive. Learn more.Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
